Evidence map›Paper›PMID 35661972›Full record

ArticleImmunologic research2022

In-utero exposure to immunosuppressive medications resulting in abnormal newborn screening for severe combined immunodeficiency: a case series on natural history and management.

Hallie A Carol, Elisa N Ochfeld, Aisha Ahmed

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Immunologic research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. [Newborn screening for severe combined immunodeficiencies (SCID) in Germany].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hallie A CarolGeneral Academic Pediatrics, McGaw Medical Center Northwestern University / Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. hallieannecarol@gmail.com.ORCID 0000-0001-8890-9785
Elisa N OchfeldPediatric Allergy/Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Aisha AhmedPediatric Allergy/Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Northwestern University · USLurie Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exposure to immunosuppressive medication in utero is an important cause of secondary T cell lymphopenia in infancy, which can be detected via T cell receptor excision circle (TREC) quantification on severe combined immunodeficiency (SCID) newborn screening (NBS). At present, there is a paucity of literature surrounding management of these infants. A protocol including recommendations for vaccinations and follow-up is needed to augment care. Patients referred to immunology for abnormal TREC results on NBS were identified as having in utero exposure to immunosuppressive medications and were followed until lymphopenia improved. The natural history of these patients' lymphopenia was used to develop general management guidelines. Four infants with low TRECs secondary to in utero immunosuppressive exposure were evaluated. Medication exposures included azathioprine, infliximab, hydroxychloroquine, and fingolimod. All infants were born full term. TRECs ranged from 101-206 (normal value in IL ≥ 250 at time of testing, B-actin control). T cell lymphopenia (CD3 < 1500) was present in 50% of cases. Undetectably low effector CD4 naïve T cell population was present in 100% of cases. Mitogen proliferation was uniformly normal. Severity of TREC abnormality did not correlate with presence of T cell lymphopenia. Immune abnormalities normalized in 75% patients by age 4 months. All age-appropriate vaccinations, including live vaccines, were administered to all patients by age 4 months. It is critical to assess for in utero immunosuppressive exposure in infants with abnormal TREC results on NBS. In the infants evaluated, secondary T cell lymphopenia associated with maternal immunosuppressive use resolved or significantly improved by age 4 months. Once abnormal TREC count is deemed to be secondary to in utero immunosuppression and there are no other contraindications, infants may safely receive live vaccination, are able to drink breast milk, and do not require prophylactic anti-microbials.

Indexed as

LymphopeniaSevere Combined ImmunodeficiencyVaccinesActinsAzathioprineFemaleFingolimod HydrochlorideHumansHydroxychloroquineInfantInfant, NewbornInfliximabMitogensNeonatal ScreeningReceptors, Antigen, T-CellActinsAzathioprineFingolimod HydrochlorideHydroxychloroquineInfliximabMitogensReceptors, Antigen, T-CellVaccinesAbnormal newborn screenAbnormal T cell receptor excision circle (TREC)LymphopeniaMaternal immunosuppressionSevere combined immunodeficiency (SCID)

Identifiers

PMID35661972
OpenAlexW4281608572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.